The EXenatide Study of Cardiovascular Event Lowering (EXSCEL) was a randomized, placebo-controlled, global pragmatic clinical trial designed to assess the effect of subcutaneous once-weekly GLP-1 RA exenatide (EQW) 2 mg on cardiovascular outcomes in 14,752 participants with type 2 diabetes mellitus and a range of cardiovascular risk. The trial aimed to provide insight into the effects of open-label SGLT2i use in parallel with or shortly after once-weekly GLP-1 RA exenatide (EQW) on cardiorenal outcomes.

New Insights From This Study

Combination exenatide QW and SGLT2i caused significant reduction in cardiovascular death compared to exenatide alone or neither drug class.

All-cause mortality risk decreased with the combination, compared to exenatide alone or placebo.

SGLT2i-mediated eGFR slope improvement was consistent

Combination GLP-1 RA and SGLT2i may provide additional cardiovascular and mortality benefit to GLP-1 RA alone, without any increase in the risk of hypoglycemia.

Ref: https://cardiab.biomedcentral.com/articles/10.1186/s12933-019-0942-x.

1 Comment

  1. togel hkg

    Do you have a spam problem on this blog; I also am a blogger, and I was wanting to know your situation; many of us have developed some nice practices and we are looking to swap methods with others, please shoot me an email if interested.

Leave a Reply

Your email address will not be published. Required fields are marked *